Precision Oncology Market Size was valued at USD 69.2 Billion in 2022. The Precision Oncology market industry is projected to grow from USD 76.8 Billion in 2023 to USD 177.0 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 11.00% during the forecast period (2024 - 2032). Increased adoption of telemedicine and digital health solutions facilitates remote access to specialized oncology care, which is one of the key market drivers enhancing the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Market CAGR for precision oncology is being driven by the growing adoption of telemedicine. Telemedicine platforms enable patients to consult with oncologists, genetic counselors, and precision medicine experts remotely, facilitating timely access to personalized treatment recommendations and molecular profiling services. Additionally, telemedicine enables remote monitoring of treatment responses, disease progression, and adverse effects, enhancing patient management and care coordination. Furthermore, telemedicine platforms facilitate the integration of genomic data into clinical decision-making processes, allowing for real-time interpretation of molecular test results and treatment adjustments based on evolving patient needs. Overall, the widespread adoption of telemedicine expands patient access to precision oncology services, improves healthcare delivery, and drives market growth in the Precision Oncology Market.
The rising incidence of cancer globally is a significant driver of the Precision Oncology Market. As the prevalence of various cancer types continues to increase, there is a growing demand for effective and personalized treatment options. Precision oncology offers tailored therapeutic approaches based on individual patient characteristics, including genetic mutations, tumor biology, and molecular profiles. By leveraging advanced genomic technologies and targeted therapies, precision oncology aims to improve treatment outcomes, minimize adverse effects, and prolong survival for cancer patients. Additionally, the rising burden of cancer underscores the urgent need for innovative diagnostic tools, companion diagnostics, and molecular profiling services to guide treatment decisions and optimize patient care. Therefore, the escalating incidence of cancer fuels the demand for precision oncology solutions, driving market growth and advancements in cancer care.
Advancements in genomic technologies are driving the Precision Oncology Market by revolutionizing our understanding of cancer biology and guiding personalized treatment strategies. Next-generation sequencing (NGS), gene expression profiling, and single-cell sequencing techniques enable comprehensive analysis of tumor genomes, identifying key genetic alterations driving cancer development and progression. These advancements facilitate the discovery of novel biomarkers, therapeutic targets, and predictive signatures, enabling more precise patient stratification and treatment selection in precision oncology. Additionally, genomic technologies empower the development of companion diagnostics, which help match patients with targeted therapies based on their molecular profiles. Furthermore, ongoing innovations in bioinformatics and data analytics enable the interpretation of complex genomic data, supporting clinical decision-making and treatment optimization. Overall, advancements in genomic technologies drive the adoption of precision oncology approaches, improving patient outcomes and driving market revenue growth in the Precision Oncology Market.
For instance, the BGI Genomics and the University of Pécs (UP) have collaborated to establish a joint laboratory in Hungary. The purpose of this partnership is to commence official operations aimed at expediting the advancement of genomic sequencing and clinical diagnostic services. Additionally, the collaboration aims to bolster the innovative precision medicine initiatives of BGI Genomics and UP in the Central and Eastern European region.
The Precision Oncology Market segmentation, based on product type, includes Diagnostics and Therapeutics. In 2023, the diagnostics segment dominated the market, accounting for 65% of market revenue due to their pivotal role in guiding treatment decisions and patient management. These products encompass a wide range of tools and technologies, including molecular diagnostics, imaging modalities, and liquid biopsies, enabling comprehensive tumor profiling and identification of actionable genetic alterations. By facilitating early detection, prognostication, and treatment response monitoring, diagnostics products empower oncologists to personalize treatment regimens and optimize patient outcomes, driving their extensive adoption and market dominance in precision oncology.
Therapeutics products are experiencing the highest Compound Annual Growth Rate (CAGR) in the Precision Oncology Market due to advancements in targeted therapies, immunotherapies, and precision medicine approaches. These products offer personalized treatment options tailored to individual patients based on their molecular profiles, genetic mutations, and tumor characteristics. With an increasing understanding of cancer biology and the development of novel therapeutic agents, therapeutic products provide innovative and effective treatment options for various cancer types, driving their adoption and market growth in precision oncology.
Figure 1: Precision Oncology Market, by Product Type, 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The Precision Oncology Market segmentation, based on cancer type, includes Breast Cancer, Lung Cancer, Colorectal Cancer, Skin Cancer, Prostate Cancer, Stomach Cancer and Other. In 2023, the breast cancer category generated the most income due to its high incidence and diverse molecular subtypes. Precision oncology approaches offer tailored treatment options based on the specific molecular characteristics of breast tumors, including hormone receptor status, HER2 expression, and genetic mutations. With advancements in targeted therapies, immunotherapies, and hormone therapies, precision medicine has significantly improved outcomes for breast cancer patients, driving its dominance in the Precision Oncology Market.
Lung cancer is experiencing the highest Compound Annual Growth Rate (CAGR) in the Precision Oncology Market due to several factors. These include the rising incidence of lung cancer globally, increasing adoption of precision medicine approaches for molecular profiling and targeted therapies, and advancements in immunotherapy options. Additionally, the development of novel diagnostic tools and companion diagnostics for lung cancer detection and treatment selection further drives market growth, positioning lung cancer as a key growth driver in precision oncology.
The Precision Oncology Market segmentation, based on end-user, includes Hospitals, Diagnostic Centers, Research & Academic Institutes and Other. In 2023, the hospitals category generated the most income due to their central role in cancer diagnosis, treatment, and patient care. Hospitals serve as primary hubs for oncology services, offering comprehensive diagnostic capabilities, advanced treatment modalities, and multidisciplinary care teams. With an increasing demand for precision oncology approaches, hospitals are at the forefront of adopting molecular profiling technologies, targeted therapies, and personalized treatment regimens, driving their extensive adoption and market dominance in precision oncology services.
Diagnostic centers are experiencing the highest Compound Annual Growth Rate (CAGR) in the Precision Oncology Market due to their specialized focus on cancer diagnostics and molecular profiling services. These centers offer state-of-the-art diagnostic technologies, including next-generation sequencing, liquid biopsies, and imaging modalities, facilitating comprehensive tumor characterization and personalized treatment planning. Additionally, diagnostic centers provide rapid and accurate test results, enabling timely intervention and treatment optimization for cancer patients. With increasing demand for precision oncology approaches, diagnostic centers are witnessing significant growth, driving their highest CAGR in the market.
By region, the study provides the market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American Precision Oncology market area will dominate this market. North America has secured the largest market share in the Precision Oncology Market due to several factors. These include advanced healthcare infrastructure, significant investments in research and development, and a high prevalence of cancer. Additionally, the region boasts a large number of biotechnology and pharmaceutical companies, academic research institutions, and healthcare facilities specializing in precision oncology. Moreover, supportive regulatory frameworks, favorable reimbursement policies, and increasing adoption of personalized medicine approaches further contribute to North America's dominance in the Precision Oncology Market.
Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: PRECISION ONCOLOGY MARKET SHARE BY REGION 2023 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe Precision Oncology market accounts for the second-largest market share due to the high prevalence of cancer. Europe has secured the second-largest market share in the Precision Oncology Market due to several factors. These include advanced healthcare systems, significant investments in research and development, and a high prevalence of cancer. Additionally, Europe boasts a strong network of academic research institutions, healthcare facilities, and biotechnology companies specializing in precision oncology. Moreover, supportive regulatory frameworks, collaborative research initiatives, and increasing adoption of personalized medicine approaches contribute to Europe's prominence in the Precision Oncology Market. Further, the German Precision Oncology market held the largest market share, and the UK Precision Oncology market was the fastest growing market in the European region.
The Asia-Pacific Precision Oncology Market is expected to grow at the fastest CAGR from 2024 to 2032. The Asia Pacific region is experiencing the highest Compound Annual Growth Rate (CAGR) in the Precision Oncology Market due to several factors. These include the rising incidence of cancer, increasing healthcare expenditure, and growing adoption of precision medicine approaches. Additionally, advancements in healthcare infrastructure, expanding access to molecular profiling technologies, and rising awareness about personalized treatment options contribute to market growth in the Asia Pacific region. Moreover, supportive government initiatives, strategic partnerships, and collaborations drive innovation and market expansion in precision oncology across the region. Moreover, China’s Precision Oncology market held the largest market share, and the Indian Precision Oncology market was the fastest growing market in the Asia-Pacific region.
Precision Oncology Key Market Players & Competitive Insights
Leading players In the Precision Oncology Market, such as Roche, Illumina, and Thermo Fisher Scientific, are focusing on innovation and strategic collaborations. They invest in research and market developments to develop advanced molecular profiling technologies, targeted therapies, and companion diagnostics. Additionally, these companies engage in strategic partnerships with healthcare providers, academic institutions, and biopharmaceutical companies to expand their product portfolios and market presence. Moreover, they prioritize customer-centric approaches, aiming to provide comprehensive precision oncology solutions to improve patient outcomes and drive market competitiveness.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global Precision Oncology industry to benefit clients and increase the market sector. In recent years, the Precision Oncology industry has offered some of the most significant advantages to diagnostics. Major players in the Precision Oncology market include Roche, Illumina, Inc., Thermo Fisher Scientific Inc., Qiagen N.V., Agilent Technologies, Inc., Foundation Medicine. Inc., Guardant Health, Inc., Myriad Genetics, Inc., NanoString Technologies, Inc., Exact Sciences Corporation and others, are attempting to increase market demand by investing in research and development operations.
Roche, a global healthcare company headquartered in Switzerland, is a key player in the Precision Oncology Market. With a rich history of innovation, Roche is at the forefront of developing advanced diagnostics and therapeutics for cancer care. The company's precision oncology portfolio includes molecular diagnostics, companion diagnostics, targeted therapies, and immunotherapies aimed at improving patient outcomes and personalized treatment approaches. Roche's commitment to research and development, strategic partnerships, and collaborations with academic institutions and healthcare providers drive innovation in precision oncology. Leveraging cutting-edge technologies and a deep understanding of cancer biology, Roche continues to advance the field of precision medicine, shaping the future of cancer care worldwide.
Qiagen N.V., a leading provider of sample and assay technologies for molecular diagnostics and life sciences, plays a significant role in the Precision Oncology Market. Headquartered in the Netherlands, Qiagen specializes in developing innovative solutions for molecular testing, including next-generation sequencing (NGS) assays, liquid biopsy technologies, and companion diagnostics. Qiagen's precision oncology portfolio enables comprehensive tumor profiling, treatment selection, and monitoring of treatment response, empowering healthcare providers to deliver personalized cancer care. The company's commitment to research and development, strategic collaborations with biopharmaceutical companies and academic institutions, and global presence contribute to its prominence in the Precision Oncology Market. Qiagen continues to drive advancements in precision oncology, supporting improved patient outcomes and advancing cancer diagnostics and treatment worldwide.
Key Companies in the Precision Oncology market include
Precision Oncology Industry Developments
December 2022: Roche announced the introduction of a medication for a rare autoimmune condition, neuromyelitis optica spectrum disorder (NMOSD), in India by the conclusion of 2023. This drug is specifically tailored for precision medicine.
June 2022: Roche introduced the BenchMark ULTRA PLUS system for cancer diagnostics, facilitating timely and targeted patient care.
| Report Attribute/Metric | Details |
| Market Size 2022 | USD 69.2 Billion |
| Market Size 2023 | USD 76.8 Billion |
| Market Size 2032 | USD 177.0 Billion |
| Compound Annual Growth Rate (CAGR) | 11.00% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2019-2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Product Type, Cancer Type, End-User, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Roche, Illumina, Inc., Thermo Fisher Scientific Inc., Qiagen N.V., Agilent Technologies, Inc., Foundation Medicine. Inc., Guardant Health, Inc., Myriad Genetics, Inc., NanoString Technologies, Inc. and Exact Sciences Corporation |
| Key Market Opportunities | · Increased collaborations between biotechnology companies, pharmaceutical firms, academic institutions, and healthcare organizations |
| Key Market Dynamics | · Growing Adoption of Telemedicine and Rising Incidence of Cancer |
Frequently Asked Questions (FAQ) :
The Precision Oncology Market size was valued at USD 76.8 Billion in 2023.
The global market is projected to grow at a CAGR of 11.00% during the forecast period, 2024-2032.
North America had the largest share in the global market
The key players in the market are Roche, Illumina, Inc., Thermo Fisher Scientific Inc., Qiagen N.V., Agilent Technologies, Inc., Foundation Medicine, Inc., Guardant Health, Inc., Myriad Genetics, Inc., NanoString Technologies, Inc. and Exact Sciences Corporation Company.
The diagnostics category dominated the market in 2023.
The hospitals category had the largest share in the global market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
